2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-144387
    Antibacterial agent 71 98%
    ient S. Tm and hyperpermeable Escherichia coli. The potencies against WT strains of E. coli, Acinetobacter baumannii, and Burkholderia cenocepacia are also improved considerably (up to >128-fold) with the outer-membrane permeabi
    Antibacterial agent 71
  • HY-144391
    Chitin synthase inhibitor 1 2763387-69-3 98%
    Chitin synthase inhibitor 1 is a potent and selective chitin synthase (CHS) inhibitor (IC50=0.12 mM). Chitin synthase inhibitor 1 has potent antifungal activity against drug-resistant fungi variants.
    Chitin synthase inhibitor 1
  • HY-144395
    HDAC6-IN-4 2709103-20-6 98%
    HDAC6-IN-4 (C10) is a potent, orally active and highly selective HDAC6 inhibitor with an IC50 value of 23 nM. HDAC6-IN-4 induces cancer cells apoptosis and shows significant antitumor efficacy, without obvious toxicity.
    HDAC6-IN-4
  • HY-144397
    LEO 134310 2089130-74-3 98%
    LEO 134310 is a selective, non-steroidal glucocorticoid receptor (GR) agonist optimized for topical research., LEO 134310 showed high affinity (EC50 of 14 nM) in a GR binding assay. LEO 134310 can be used for skin diseases.
    LEO 134310
  • HY-144618
    Antibacterial agent 74 1644387-48-3 98%
    Antibacterial agent 74 (compound 36) is an anti-Salmonella agent.
    Antibacterial agent 74
  • HY-144621
    Antibacterial agent 75 2765224-33-5 98%
    Antibacterial agent 75 (compound 24) is an antibacterial agent. Antibacterial agent 75 (compound 24) is able to re-sensitize VRSA to vancomycin.
    Antibacterial agent 75
  • HY-144639
    Carbonic anhydrase inhibitor 5 98%
    Carbonic anhydrase inhibitor 5 is a potent and selective human carbonic anhydrase (hCA) inhibitor with IC50s of 42.9, 47,6 and 6.7 nM for hCA II, hCA IX and hCA XII, respectively.
    Carbonic anhydrase inhibitor 5
  • HY-144643
    CYP51/HDAC-IN-1 2502095-64-7 98%
    CYP51/HDAC-IN-1 is a potent, orally active CYP51/HDAC dual inhibitor. CYP51/HDAC-IN-1 inhibits important virulence factors and down-regulated resistance-associated genes. CYP51/HDAC-IN-1 exhibits potent therapeutic effects for both tropical candidiasis and cryptococcal meningitis.
    CYP51/HDAC-IN-1
  • HY-144672
    A2A receptor antagonist 2 2767206-20-0 98%
    A2A receptor antagonist 2 (Compound 57) is a potent, highly selective adenosine A2A receptor (A2AR) antagonist with an IC50 of 8.3 nM.
    A2A receptor antagonist 2
  • HY-144727
    Anti-inflammatory agent 11 63932-07-0 98%
    Anti-inflammatory agent 11 (compound 16) is a potent antimycobacterial and anti-inflammatory agent. Anti-inflammatory agent 11 inhibits Mtb H37Rv and M299 growth, with MIC50 (minimum inhibitory concentration 50%) of 1.3 and 6.9 μM, respectively. Anti-inflammatory agent 11 inhibits NO through the suppression of iNOS expression, and also inhibited the production of TNF-α and IL-1β. Anti-inflammatory agent 11 can be used for tuberculosis (TB) research.
    Anti-inflammatory agent 11
  • HY-144729
    Antibacterial agent 82 3032608-35-5 98%
    Antibacterial agent 82 (compound 7p) is an antibacterial agent.
    Antibacterial agent 82
  • HY-144730
    gp120-IN-1 5948-75-4 98%
    gp120-IN-1 (compound 4e) is a potent HIV-1 gp120 inhibitor with an IC50 of 2.2 µM and CC50 of 100.90 µM. gp120-IN-1 shows anti-HIV-1 activity. gp120-IN-1 shows cytotoxicity in a dose dependent manner in SUP-T1 cells. gp120-IN-1 shows inhibition of gp120-mediated virus enter into cells.
    gp120-IN-1
  • HY-144731
    gp120-IN-2 123629-42-5 98%
    gp120-IN-2 (compound 4i) is a potent HIV-1 gp120 inhibitor with an IC50 of 7.5 µM and CC50 of 112.93 µM. gp120-IN-2 shows anti-HIV-1 activity. gp120-IN-2 shows cytotoxicity in a dose dependent manner in SUP-T1 cells.
    gp120-IN-2
  • HY-144735
    Anti-inflammatory agent 14 894496-27-6 98%
    Anti-inflammatory agent 14 (compound 28) is an anti-inflammatory agent, with a MIC50 of 2 μM for Mtb H37Rv.
    Anti-inflammatory agent 14
  • HY-144737
    Anti-inflammatory agent 15 474516-87-5 98%
    Anti-inflammatory agent 15 (compound 29) is a potent antimycobacterial and anti-inflammatory agent. Anti-inflammatory agent 15 inhibits Mtb H37Rv and M299 growth, with MIC50 (minimum inhibitory concentration 50%) of 2.3 and 7.8 μM, respectively. Anti-inflammatory agent 15 inhibits NO through the suppression of iNOS expression, and also inhibited the production of TNF-α and IL-1β. Anti-inflammatory agent 15 can be used for tuberculosis (TB) research.
    Anti-inflammatory agent 15
  • HY-144738
    Dual FAAH/sEH-IN-1 2756099-59-7 98%
    Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual sEH (soluble epoxide hydrolase) and FAAH (fatty acid amide hydrolase) inhibitor, with IC50 values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase.
    Dual FAAH/sEH-IN-1
  • HY-144773
    Loxoprofenol-SRS 83648-76-4 98%
    Loxoprofenol-SRS, an active metabolite of Loxoprofen, is a new intravenous NSAID. Loxoprofenol-SRS exhibits significantly stronger anti-inflammatory and analgesic activities.
    Loxoprofenol-SRS
  • HY-144781
    CXCR2 antagonist 5 98%
    CXCR2 antagonist 5 (compound 25) is a potent CXCR2 antagonist. CXCR2 antagonist 5 shows potent CXCR2 binding affinity (IC50=0.013 µM) and calcium mobilization (IC50=0.1 µM)[ 1].
    CXCR2 antagonist 5
  • HY-144783
    CXCR2 antagonist 6 98%
    CXCR2 antagonist 6 (compound 35c) is a potent CXCR2 antagonist. CXCR2 antagonist 6 shows potent CXCR2 binding affinity (IC50=0.044 µM) and calcium mobilization (IC50=0.66 µM)[ 1].
    CXCR2 antagonist 6
  • HY-144784
    CXCR2 antagonist 7 98%
    CXCR2 antagonist 7 (compound 19) is a potent CXCR2 antagonist. CXCR2 antagonist 7 shows potent CXCR2 binding affinity (IC50=0.044 µM) and calcium mobilization (IC50=0.66 µM)[ 1].
    CXCR2 antagonist 7
Cat. No. Product Name / Synonyms Application Reactivity